JP drafts for public comments, September 2 - 30, 2019
New General Test
- 2.05 Size Exclusion Chromatography[54.7KB] (001-1909-1eng.pdf)
JP drafts for public comments, September 2 - November 30, 2019
Revised General Test
- 2.66 Elemental Impurities[433KB] (002-1909-1eng.pdf)
Briefing on Proposed Revision
General Test "2.66 Elemental Impurities Procedures"[44.9KB]New monographs
- Bicalutamide[298KB] (003-1909-1eng.pdf)
- Celecoxib[208KB] (004-1909-1eng.pdf)
- Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution[129KB] (005-1909-1eng.pdf)
- Ethyl Loflazepate[118KB] (006-1909-1eng.pdf)
- Ethyl Loflazepate Tablets[101KB] (007-1909-1eng.pdf)
- Fenofibrate[226KB] (008-1909-1eng.pdf)
- Fenofibrate Tablets[298KB] (009-1909-1eng.pdf)
- Gefitinib[213KB] (010-1909-1eng.pdf)
- Glucagon (Genetical Recombination)[361KB] (011-1909-1eng.pdf)
- Heparin Sodium Lock Solution[161KB] (012-1909-1eng.pdf)
- Heparin Sodium Solution for Dialysis[162KB] (013-1909-1eng.pdf)
- Irinotecan Hydrochloride Injection[129KB] (014-1909-1eng.pdf)
- Methotrexate for Injection[124KB] (015-1909-1eng.pdf)
- Rilmazafone Hydrochloride Hydrate[227KB] (016-1909-1eng.pdf)
- Rilmazafone Hydrochloride Tablets[97.5KB] (017-1909-1eng.pdf)
- Rosuvastatin Calcium[290KB] (018-1909-1eng.pdf)
- Rosuvastatin Calcium Tablets[220KB] (019-1909-1eng.pdf)
- Zopiclone[201KB] (020-1909-1eng.pdf)
- Zopiclone Tablets[133KB] (021-1909-1eng.pdf)
Ultraviolet-visible reference spectra
- Bicalutamide[45.0KB] (022-1909-1eng.pdf)
- Celecoxib[44.1KB] (023-1909-1eng.pdf)
- Ethyl Loflazepate[43.1KB] (024-1909-1eng.pdf)
- Fenofibrate[31.8KB] (025-1909-1eng.pdf)
- Gefitinib[45.2KB] (026-1909-1eng.pdf)
- Rilmazafone Hydrochloride Hydrate[46.5KB] (027-1909-1eng.pdf)
- Rosuvastatin Calcium[49.2KB] (028-1909-1eng.pdf)
- Zopiclone[42.3KB] (029-1909-1eng.pdf)
Infrared reference spectra
- Bicalutamide[125KB] (030-1909-1eng.pdf)
- Celecoxib[110KB] (031-1909-1eng.pdf)
- Ethyl Loflazepate[138KB] (032-1909-1eng.pdf)
- Fenofibrate[130KB] (033-1909-1eng.pdf)
- Gefitinib[137KB] (034-1909-1eng.pdf)
- Rilmazafone Hydrochloride Hydrate[136KB] (035-1909-1eng.pdf)
- Rosuvastatin Calcium[133KB] (036-1909-1eng.pdf)
- Zopiclone[145KB] (037-1909-1eng.pdf)
To send the comment on these drafts, the guidance is as follows:
- Download the form for comments in Word format[67.5KB]
- Fill in the form
- Prepare and attach the supportive data that scientifically validate the comment when appropriate
- Send it to the email address: JPdraft1909-1eng[at]pmda.go.jp
Note: For the purpose of security, this email address is partly incorrect. Please replace [at] with @ when sending an email.
Related Information
Note: The information provided with the comment may be released to the public whenever necessary (except the individual name, organization, address, telephone & fax numbers and e-mail address or the attached supportive data).